Bristol Myers and Pfizer said on Thursday they will start selling their blockbuster blood thinner, Eliquis, directly to ...

The companies' new effort would bypass traditional middlemen to cut the drug's monthly cost from a list price of around $606 ...

The reduced rate will still be almost 10 times the average monthly out-of-pocket costs paid by commercially insured patients.

Bristol Myers' Reblozyl missed its primary goal in a Phase 3 anemia trial but showed positive secondary outcomes in ...

The program is the latest example of pharmaceutical companies bypassing traditional drug distribution channels for people who ...

The joint venture is launching a direct-to-consumer service of Eliquis after discussions with the Trump administration.

Pfizer and Bristol Myers Squibb have launched a direct-to-patient program offering their blood thinner Eliquis at a 40% discount for cash-paying patients.  The list price for Eliquis (apixaban) is ...

Bristol Myers and Pfizer will sell Eliquis directly to U.S. patients at a discounted rate with transparent pricing and ...

The direct-to-consumer (DTC) platform – called Eliquis 360 Support – will offer Eliquis (apixaban) to patients who pay for ...

Apixaban would still cost patients 9 times more through the Eliquis 360 Support program than with commercial insurance.

Taking a page from Eli Lilly and Novo Nordisk, who have launched online programs to sell their diabetes and obesity drugs ...

Pharmaceutical giants introduce an insurance-free pathway for top anticoagulant Eliquis, following similar direct-to-patient models from Eli Lilly and Novo Nordisk.